Literature DB >> 9084790

The effect of maternal viral load on the risk of perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group.

D M Thea1, R W Steketee, V Pliner, K Bornschlegel, T Brown, S Orloff, P B Matheson, E J Abrams, M Bamji, G Lambert, E A Schoenbaum, P A Thomas, M Heagarty, M L Kalish.   

Abstract

OBJECTIVE: To determine the effect of maternal viral load at delivery on the risk of perinatal transmission of HIV-1.
DESIGN: A nested case-control study within a prospectively followed cohort of HIV-1-infected pregnant women and their infants.
SETTING: The multicenter New York City Perinatal HIV Transmission Collaborative Study. PARTICIPANTS: Fifty-one women who gave birth to HIV-1 infected infants were frequency-matched within CD4+ cell count quintiles with 54 non-transmitting mothers. MAIN OUTCOME MEASURES: Maternal quantity of HIV-1 viral RNA was assayed in plasma obtained near delivery using the nucleic acid sequence-based amplification assay system.
RESULTS: Viral RNA was detected in 73 (70%) out of 105 women and the median viral load was 16,000 RNA copies/ml in transmitters and 6,600 in non-transmitters (P < 0.01). When adjusted for maternal CD4+ count near delivery, women with measurable viral load were nearly sixfold more likely to transmit HIV-1 than women with viral load below detection [adjusted odds ratio (AOR), 5.8; 95% confidence interval (CI), 2.2 15.5]. The odds ratio for perinatal transmission of log10 viral load, adjusted for CD4 count was 2.7 (95% CI, 1.5-5.1). When stratified by the stage of HIV-1 disease, the only group with significant association between log10 viral load and transmission were AIDS-free women with CD4+ count > 500 x 10(6)/l (AOR, 9.1; 95% CI, 2.6-31.5).
CONCLUSIONS: High maternal viral load increases the likelihood of perinatal transmission of HIV-1 in women without AIDS and advanced immunosuppression. HIV-1 infected pregnant women without advanced disease, shown by others to have the lowest risk of perinatal transmission, may benefit the most from efforts to identify and decrease viral load at delivery.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9084790     DOI: 10.1097/00002030-199704000-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  20 in total

Review 1.  Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics.

Authors:  J Lew; P Reichelderfer; M Fowler; J Bremer; R Carrol; S Cassol; D Chernoff; R Coombs; M Cronin; R Dickover; S Fiscus; S Herman; B Jackson; J Kornegay; A Kovacs; K McIntosh; W Meyer; N Michael; L Mofenson; J Moye; T Quinn; M Robb; M Vahey; B Weiser; T Yeghiazarian
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

Review 2.  Options for prevention of HIV transmission from mother to child, with a focus on developing countries.

Authors:  Louise Kuhn; Ingrid Peterson
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Challenges in initiating antiretroviral therapy in 2010.

Authors:  Cécile L Tremblay; Jean-Guy Baril; David Fletcher; Donald Kilby; Paul Macpherson; Stephen D Shafran; Mark W Tyndall
Journal:  Can J Infect Dis Med Microbiol       Date:  2010-08       Impact factor: 2.471

4.  Human immunodeficiency virus infection in pregnancy.

Authors:  Y Arikan; D R Burdge
Journal:  Can J Infect Dis       Date:  1998-09

Review 5.  British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998).

Authors:  G P Taylor; E G Lyall; D Mercey; R Smith; T Chester; M L Newell; G Tudor-Williams
Journal:  Sex Transm Infect       Date:  1999-04       Impact factor: 3.519

6.  Modeling interventions to assess HIV epidemic impact in Africa.

Authors:  Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

7.  Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda.

Authors:  Francis Bajunirwe; Iyesatta Massaquoi; Stephen Asiimwe; Moses R Kamya; Eric J Arts; Christopher C Whalen
Journal:  Afr Health Sci       Date:  2004-12       Impact factor: 0.927

8.  Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates.

Authors:  Adrian B McDermott; Jacque Mitchen; Shari Piaskowski; Ivna De Souza; Levi J Yant; Jason Stephany; Jessica Furlott; David I Watkins
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study.

Authors:  Ingrid T Katz; Roger Shapiro; Daner Li; Usha Govindarajulu; Bruce Thompson; D Heather Watts; Michael D Hughes; Ruth Tuomala
Journal:  J Acquir Immune Defic Syndr       Date:  2010-05-01       Impact factor: 3.731

10.  Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response.

Authors:  Vlada V Melekhin; Bryan E Shepherd; Samuel E Stinnette; Peter F Rebeiro; Gema Barkanic; Stephen P Raffanti; Timothy R Sterling
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.